Press releases
EG 427 appoints Chief Medical Officer
EG 427 announces the appointment of Cornelia Haag-Molkenteller as Chief Medical Officer
EG 427 completes Series A financing
EG 427 announces €12 million Series A financing to advance its HSV-1 based gene therapy
Appointment of new VP of Research
EG 427 appoints Grzegorz Sarek, Ph.D., as Vice President of Research
News
Bladder Buzz talks about our innovative approach to NDO
EG 427 - a success story
EG 427 is the success story of the month presented by The SATT Network.
EG 427 wins key funding from Bpifrance
EG 427 received 360 000 € from Bpifrance to advance the pharmaceutical development of its first gene therapy candidate.
EG 427 recognised in iLab 2020
Events
EG 427 will be presenting at BIO Europe Spring 2023
2023-02-07
See you at BioFIT 2022!
2022-11-14We'll be in BioFIT in Strasbourg on November 29-30, 2022. Our CEO, Philippe Chambon, will be presenting the company in the Startup Slam.
Come and meet us to learn more about nrHSV-1.
EG427 will be presenting at Bio-Europe Spring 2022
2022-11-04Attend our presentation to know more about the company. Looking forward to e-meet you there!
Meet us at Cell Gene Med 2022 in Barcelona
2022-11-04Our CEO, Philippe Chambon MD, PhD will be presenting EG 427 and our gene therapy platform.
